Efficacy of lycorine thioester hydrochloride against coxsackievirus A16 in vivo

doi:10.19803/j.1672-8629.20220625

Abstract

Abstract: Objective To investigate the efficacy of lycorine thioester hydrochloride against coxsackievirus A16 (CVA16) in vivo. Methods A mouse model of CVA16 infection was established via intraperitoneal injection of CVA16 in ICR mice aged 10 to 11 days. The experimental groups were divided into 1.0, 0.5 and 0.25 mg·kg^-1 lycorine thioester hydrochloride groups, 50 mg·kg^-1 RBV control group, virus control group, and the normal control group. The incidence of infections, survival rate and average survival of mice after virus infection were detected. The expression level of the viral protein in muscle tissue was detected by Western-blot assay. Cytopathic effect assay (CPE) was used to detect the viral titer in muscle tissue. Hematoxylin-eosin(HE) staining was used to detect the pathological changes of muscle tissue. Results Compared with the virus control group, administration of lycorine thioester hydrochloride 1.0 and 0.5 mg·kg^-1 could significantly reduce the viral titer and viral protein expression in muscle tissue, mitigate the inflammatory injury caused by CVA16 infection, delay the pathogenesis of mice, significantly prolong the average survival of mice, and increase the survival rate of mice. Conclusion Administration of lycorine thioester hydrochloride 1.0 and 0.5 mg·kg^-1 has a significant protective effect on CVA16-infected mice, suggesting that lycorine thioester hydrochloride may be a potential drug for the treatment of hand, foot, and mouth disease (HFMD).

Key words: lycorine thioester hydrochloride, coxsackievirus A16, hand, foot, and mouth disease, antiviral efficacy in vivo, mice

CLC Number:

R917
R978.7

WANG Huiqiang, YAN Haiyan, LI Xingqiong, YANG Jie, LI Yuhuan. Efficacy of lycorine thioester hydrochloride against coxsackievirus A16 in vivo[J]. Chinese Journal of Pharmacovigilance, 2023, 20(1): 79-84.

References

[1] ESPOSITO S, PRINCIPI N. Hand, foot and mouth disease: current knowledge on clinical manifestations, epidemiology, aetiology and prevention[J]. Eur J Clin Microbiol Infect Dis, 2018, 37(3): ???-???.
[2] CAI K, WANG Y, GUO Z, et al.Clinical characteristics and managements of severe hand, foot and mouth disease caused by enterovirus A71 and coxsackievirus A16 in Shanghai, China[J]. BMC Infect Dis, 2019, 19(1): 285.
[3] SOLOMON T, LEWTHWAITE P, PERERA D, et al.Virology, epidemiology, pathogenesis, and control of enterovirus 71[J]. Lancet Infect Dis, 2010, 10(11): 778-790.
[4] WU TN, TSAI SF, LI SF, et al.Sentinel surveillance for enterovirus 71, Taiwan, 1998[J]. Emerg Infect Dis, 1999, 5(?): 458-460.
[5] HE SJ, HAN JF, DING XX, et al.Characterization of enterovirus 71 and coxsackievirus A16 isolated in hand, foot, and mouth disease patients in Guangdong, 2010[J]. Int J Infect Dis, 2013, 17(11): e1025-e1030.
[6] XU W, LIU CF, YAN L, et al.Distribution of enteroviruses in hospitalized children with hand, foot and mouth disease and relationship between pathogens and nervous system complications[J]. Virol J, 2012, 9: 8.
[7] HOOI YT, ONG KC, TAN SH, et al.Coxsackievirus A16 in a 1-Day-Old mouse model of central nervous system infection shows lower neurovirulence than enterovirus A71[J]. J Comp Pathol, 2020, 176: 19-32.
[8] LI ZQ, QIN ZQ, TAN HF, et al.Analysis of the coverage of inactivated enterovirus 71 (EV71) vaccine and adverse events following immunization with the EV71 vaccine among children from 2016 to 2019 in Guangzhou[J]. Expert Rev Vaccines, 2021, 20(7): 907-918.
[9] QING X, QING FC, WAN QY, et al.Interchangeability of two enterovirus 71 inactivated vaccines in Chinese children: a phase IV, open-label, and randomized controlled trial[J]. Vaccine, 2020, 38(12): 2671-2677.
[10] HU YF, JIA LP, YU FY, et al.Molecular epidemiology of coxsackievirus A16 circulating in children in Beijing, China from 2010 to 2019[J]. World J Pediatr, 2021,17(5): 508-516.
[11] YI L, ZENG H, ZHENG H, et al.Molecular surveillance of coxsackievirus A16 in southern China, 2008-2019[J]. Arch Virol, 2021, 166(6): 1653-1659.
[12] LIU J, YANG Y, XU Y, et al.Lycorine reduces mortality of human enterovirus 71-infected mice by inhibiting virus replication[J]. Virol J, 2011, 8: 483.
[13] LI SY, CHEN C, ZHANG HQ, et al.Identification of natural compounds with antiviral activities against SARS-associated coronavirus[J]. Antiviral Research, 2005, 67(1): 18-23.
[14] WANG P, LI LF, WANG QY, et al.Anti-dengue-virus activity and structure-activity relationship studies of lycorine derivatives[J]. Chem Med Chem, 2014, 9(7): 1522-1533.
[15] HE J, QI WB, WANG L, et al.Amaryllidaceae alkaloids inhibit nuclear-to-cytoplasmic export of ribonucleoprotein (RNP) complex of highly pathogenic avian influenza virus H5N1[J]. Influenza Other Respir Viruses, 2013, 7(6): 922-931.
[16] CHEN H, LAO Z, XU J, et al.Antiviral activity of lycorine against Zika virus in vivo and in vitro[J]. Virology, 2020, 546: 88-97.
[17] JIN YH, MIN JS, JEON S, et al.Lycorine, a non-nucleoside RNA dependent RNA polymerase inhibitor, as potential treatment for emerging coronavirus infections[J]. Phytomedicine, 2021, 86:153440.
[18] WANG HQ, GUO TT, YANG YJ, et al.Lycorine derivative LY-55 inhibits CVA16 and CVA16 replication through downregulating autophagy[J]. Front Cell Infect Microbiol, 2019, 9: 277.
[19] REED LJ, MUENCH H.A simple method of estimating fifty percent endpoints[J]. Am J Epidemiol, 1938, 27: 493-497.
[20] XU L, SU WH, JIN J, et al.Identification of luteolin as enterovirus 71 and Coxsackievirus A16 inhibitors through reporter viruses and cell viability-based screening[J]. Viruse, 2014, 6(7): 2778-2795.
[21] WANG B, LI J, WANG Y, et al.Understanding the epidemiological characteristics of EV71 and CVA16 infection to aid the diagnosis and treatment of hand, foot, and mouth disease[J]. J Med Virol, 2019, 91(2): 201-207.
[22] WANG HQ, LIU SY, LI YH.Establishment of CVA16 animal models with 2-week-old ICR mice[J]. Chin Med Biotechnol(中国医药生物技术), 2018, 13(3): 268-271.